

**İSİM: BURHAN FERHANOGLU**

**ÜNVAN: Profesör Doktor**

**BÖLÜM: Hematoloji**

#### **Özet özgeçmiş**

- 1972 Vefa Lisesi İstanbul
- 1978 İstanbul Tıp Fakültesi
- 1978-1982 İstanbul Üniversitesi Tıp Fakültesi İç Hastalıkları Bilim Dalı Resident
- 1982-1984 Bursa Askeri Hastanesi, İç Hastalıkları, Askeri Hizmet
- 1984-1986 Corum Devlet Hastanesi İç Hastalıkları
- 1986-1988 Cerrahpasa Tıp Fakültesi, İç Hastalıkları Bilim Dalı Hematology Fellow
- 1988-1990 Cerrahpasa Tıp Fakültesi Doçent Dr.
- 1990-1991 University of Texas, Health Science Center, Department of Hematology, Research Fellow, Basic Science Research
- 1991-1992 Cerrahpasa Tıp Fakültesi, Doçent. Dr.
- 1992-1993 Fred Hutchinson Cancer Center, Bone Marrow Transplantation Experience
- 1993 -1994 Cerrahpasa Tıp Fakültesi, Doçent. Dr.
- 1994-2012 Cerrahpasa Tıp Fakültesi, Prof. Dr.
- 1998- .... V.K.V. Amerikan Hastanesi, Hematoloji Bölüm Başkanı
- 2012- ... Koc Üniversitesi Tıp Fakültesi, Hematoloji Bölümü
- 2018-... Koç Üniversitesi Tıp Fakültesi İç Hastalıkları Bölüm Başkanı

#### **Uluslararası Katılımlı Çok Merkezli Çalışmalar**

1. VENICE I - Open-Label, Single-Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)
2. A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

3. An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
4. A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
5. A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies
6. A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy
7. Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
8. A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - **FDA APPROVED**
9. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
10. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
11. An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17) – **FDA APPROVED**

12. Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
13. A Randomized, Open-Label, Multicenter Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
14. An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma

## Ödüller

1. **Burhan Ferhanoğlu**, Ayşe Salihoğlu, Murat Özbalak, Teoman Soysal, İhsan Karadoğan, Semra Paydaş, Evren Özdemir, Birol Yıldız, Nuri Karadurmuş, Leylagül Kaynar, Zeynep Arzu Yeğin, Ezgi Pınar Özbalak, Gülsan Sucak, Vildan Özkocaman, Pervin Topçuoğlu, Muhit Özcan, Elif Birtaş Ateşoğlu, Hakan Göker. **“Long-term Results of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma: Multi-center experience in Turkey” (Nüks/Refrakter Hodgkin Lenfoma Vakalarında Brentuximab Vedotin’in Uzun Dönem Sonuçları: Çok Merkezli Türkiye Deneyimi) Turkish Blood Network Award (TÜRKBA Ödülü)** in 43rd National Hematology Congress, Antalya, Turkey, November 1-4, 2017
2. **Ferhanoğlu B**, Beköz H, Karadurmuş N, Paydaş S, Türker A, Toptaş T, Fıratlı Tuğlular T, Sönmez M, Gülbaş Z, Özbalak M; **“Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Real-Life Experience” Best abstract award** in “4th Aegean Hematology Oncology Symposium”, Rhodes, Greece, September 21-24, 2017
3. Çetiner M, Sucak G, Aydın F, Birtaş E, Yozgatlıgil C, Kalaça S, Akı Z, Kalaycıoğlu- Beşışık S, **Ferhanoğlu B**, Gülbaş Z, Uzay A, Kaygusuz I, Fıratlı- Tuğlular T, Bayık M; **“Evaluation of Life Quality in Hematopoietic Stem Cell Transplantation Patients” (Hematopoyetik Kök Hücre Nakli Yapılan Hastalarda Yaşam Kalitesinin Değerlendirilmesi) “Clinical Hematology” award** in *Turkish Society of Hematology 33rd National Hematology Congress*, Ankara, October 16-19, 2007.

4. Demirsoy ET, Ar MC, Öngören Ş, Üre Ü, Başlar Z, **Ferhanoğlu B**, Aydın Y, Tüzüner N, Ülkü B, Aktuğlu G, Soysal T; **“Prognostic Significance of Serum Vascular Endothelial Growth Factor in Chronic Lymphocytic Leukemia” (Kronik Lenfositik Lösemide Serum Vasküler Endotelyal Büyüme Faktörü Düzeyinin Prognoz Değeri) "Schering Lymphoproliferative Disorders" second rank award in Turkish Society of Hematology 32nd National Hematology Congress, Antalya, 2006.**

5. Özbalak M, Yürüyen M, Tüzüner N, Ar MC, Güner Şİ, Çetin G, Öngören Ş, Üre Ü, Başlar Z, Soysal T, Aydın Y, Ülkü B, Demir G, Saçlı FS, **Ferhanoğlu B**; **““Response rates of germinal center and non-germinal center subtypes of DLBCL to R-CHOP chemotherapy in newly diagnosed diffuse large B cell lymphoma evaluated by immunohistochemistry” (Yeni Tanı Almış Diffüz Büyük B Hücreli Lenfomada İmmünohistokimya Aracılığıyla Değerlendirilen Doku Microarray Yöntemi ile Germinal Merkez ve Non-Germinal Merkez Tiplerinin R-Chop Kemoterapisine Yanıtları) “Roche Non-Hodgkin Lymphoma” award. (Turkish Society of Hematology Roche Industry Award) in Turkish Society of Hematology 32nd National Hematology Congress, Antalya, 2006.**

6. Ar MC, Sırma S, Hatırnaz Ö, Öngören Ş, Üre Ü, Başlar Z, Aydın Y, **Ferhanoğlu B**, Özbek U; **“Re-evaluation of Minimal Residual Disease by PCR IG/ TCR and Follow-up of Minimal Residual Disease by Detection of Translocation in patients with Acute Lymphoblastic Leukemia: Preliminary Results” (Erişkin Akut Lenfoblastik Lösemili Hastalarda Minimal Rezidüel Hastalığın PCR IG/ TCR Yeniden Yapılanması ve Translokasyon ile Tesbiti ve İzlenmesi: Ön Sonuçlar) “TSH Clinical Laboratory Hematology” award in Turkish Society of Hematology 30th National Hematology Congress, İstanbul, 2003.**

#### **Hakemi olduğu yayınlar**

1. Annals of Oncology
2. Journal of Istanbul Faculty of Medicine
3. Journal of Osmangazi Faculty of Medicine

4. Journal of Cukurova Faculty of Medicine
5. Turkish Journal of Hematology
6. Journal of Clinical Evolution

### **Bilimsel Topluluk Üyelikleri**

1. Türk Hematoloji Derneği (Turkish Society of Hematology)
2. International Society of Hematology
3. American Society of Hematology
4. European Bone Marrow Transplantation Society
5. European Hematology Association

### **Yayınlar**

#### **Ceviri Editörlüğü:**

1. Armitage JO, **Atlas of Clinical Hematology**, Lippincott Williams & Wilkins, *ACT Medikal İletişim*, 2006. (Initial Press in 2004)
2. Kern W. F., **PDQ Hematology**, BC Decker Inc. , *İstanbul Medikal Yayıncılık*, 2005 (Initial Press in 2002)

#### **Kitap Bölümleri:**

1. **Ferhanoglu B, Ozbalak M. Diffüz Büyük B Hücreli Lenfoma (Article published in Turkish, Title: Diffuse Large B Cell Lymphoma)**. Ed. Teoman Soysal HematoLog-Special Issue on Lymphoma. 2013; **3**(2): 355-81.
2. **Ferhanoglu B, Ozbalak M. Primer Merkezi Sinir Sistemi Lenfomaları (Article published in Turkish, Title: Primary Central Nervous System Lymphomas)**. Ed. Teoman Soysal HematoLog-Special Issue on Lymphoma. 2013; **3**(2): 382-94.
3. **Burhan Ferhanoglu, “Anemia: Definition-Classification, Hematology Course Book” (Anemiler: Tanım-Sınıflama, Hematoloji Ders Kitabı) Üniversite Yayın No: 4774, Cerrahpaşa Tıp Fak. Yayın No: 269, ISBN: 978-975-404-815-5, sayfa: 21-26, 2008.**

4. Teoman Soysal, **Burhan Ferhanoğlu, “Hematopoietic Stem Cell Transplantation, Hematology Course Book” (Hematopoetik Kök Hücre Nakli, *Hematoloji Ders Kitabı*)** Üniversite Yayın No: 4774, *Cerrahpaşa Tıp Fak.* Yayın No: 269, ISBN: 978-975-404-815-5, sayfa: 207-217, 2008.
5. **Burhan Ferhanoğlu, “Mechanism of Hemostasis, Hematology Course Book” (Hemostaz Mekanizması, *Hematoloji Ders Kitabı*)**, Üniversite Yayın No: 4774, *Cerrahpaşa Tıp Fak.* Yayın No: 269, ISBN: 978-975-404-815-5, sayfa: 219- 227, 2008.
6. **Burhan Ferhanoğlu, “Trombophilia, Hematology Course Book” (Trombofili, *Hematoloji Ders Kitabı*)**. Üniversite Yayın No: 4774, *Cerrahpaşa Tıp Fak.* Yayın No: 269, ISBN: 978-975-404-815-5, sayfa: 251-260, 2008.
7. **Burhan Ferhanoğlu, “Anticoagulation Treatment, Hematology Course Book” (Antikoagülan Tedavi, *Hematoloji Ders Kitabı*)**, Üniversite Yayın No: 4774, *Cerrahpaşa Tıp Fak.* Yayın No: 269, ISBN: 978-975-404-815-5, sayfa: 261-264, 2008.
8. **Burhan Ferhanoğlu, “Mechanism of Hemostasis, Tendency to Bleeding and Thrombosis” (Hemostaz Mekanizması, *Kanama ve Tromboza Eğilim*)**, Editors: Burhan Ferhanoğlu, Zafer Başlar, Tiraje Celkan, *Cerrahpaşa Tıp Fak.* Yayın No: 36, ISBN: 975-8371-47-9, sayfa: 9-16, Kasım 2003.
9. **Burhan Ferhanoğlu, “Trombophilia: Ways to Diagnosis, Tendency to Bleeding and Thrombosis” (Trombofili: Tanıda İzlenecek Yol, *Kanama ve Tromboza Eğilim*)**, Editörler: Burhan Ferhanoğlu, Zafer Başlar, Tiraje Celkan, *Cerrahpaşa Tıp Fak.* Yayın No: 36, ISBN: 975-8371-47-9, sayfa: 143-158, Kasım 2003.

#### **Uluslararası Dergilerde Yayımlanan Makaleler**

1. Ozyigit LP, Aktas EC, Senbas ZA, Ozturk AB, Ozturk E, Ergonul MO, Tabak L, Ferhanoglu B, Cetiner M, Deniz G. **The role of atopy in the pathogenesis of bleomycin pulmonary toxicity.** *Respiratory medicine.* 2019; **155**: 1-5.
2. Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigon MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yagci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodgkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W. **Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-**

**Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.** The Lancet Haematology. 2019; **6**(2): e67-e78

3. Ferhanoglu B, Ozturk E, Ozbalak M. **Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.** The New England journal of medicine. 2018; **378**(22): 2141-2.
4. Ozturk E, Akay MO, Ferhanoglu B. **Recognizing Pinch Purpura as the First Manifestation of Light-chain Amyloidosis.** Turk J Haematol. 2018; **35**(3): 208-9.
5. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J, Investigators AT. **Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.** The New England journal of medicine. 2018; **378**(6): 518-28.
6. Madran B, Keske S, Tokca G, Donmez E, Ferhanoglu B, Cetiner M, Mandel NM, Ergonul O. **Implementation of an antimicrobial stewardship program for patients with febrile neutropenia.** American journal of infection control. 2018; **46**(4): 420-4.
7. Bekoz H, Karadurmus N, Paydas S, Turker A, Toptas T, Firatli Tuğlular T, Sonmez M, Gulbas Z, Tekgunduz E, Kaya AH, Ozbalak M, Tastemir N, Kaynar L, Yildirim R, Karadogan I, Arat M, Pepedil Tanrikulu F, Ozkocaman V, Abali H, Turgut M, Kurt Yuksel M, Ozcan M, Dogu MH, Kabukcu Hacioglu S, Barista I, Demirkaya M, Koseoglu FD, Toprak SK, Yilmaz M, Demirkurek HC, Demirkol O, **Ferhanoglu B. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.** Ann Oncol. 2017; **28**(10): 2496-502.
8. Ozturk E, Ozyigit LP, Ozturk AB, Akay MO, Cetiner M, **Ferhanoglu B. Rituximab desensitization in three patients with severe rituximab allergy.** Current problems in cancer. 2017; **41**(5): 349-54.
9. Ozbalak M, Torun ES, Ozdemirli M, Ucar AR, Akpinar TS, Tascioglu C, **Ferhanoglu B. Inflammatory myofibroblastic tumor mimicking a relapse in a patient with Hodgkin's lymphoma: report of an unusual case and review of the literature.** Clinical case reports. 2017; **5**(6): 945-9.
10. Falay O, Ozturk E, Bolukbasi Y, Gumus T, Ornek S, Ozbalak M, Cetiner M, Demirkol O, **Ferhanoglu B. Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma.** Leuk Lymphoma. 2017; **58**(5): 1114-22.
11. Bekoz HS, Kantarcioglu B, Tecimer T, Uskent N, Cetiner M, **Ferhanoglu B, Sargin D. Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report.** Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion. 2016; **32**(Suppl 1): 178-80.
12. Salim O, Toptas T, Avsar E, Yucel OK, Ozturk E, **Ferhanoglu B, Geduk A, Mehtap O, Tombak A, Tiftik EN, Deveci B, Kurtoglu E, Kara O, Atagunduz IK, Tuğlular TF, Undar L. Azacitidine versus**

**decitabine in patients with refractory anemia with excess blast-Results of multicenter study.** Leuk Res. 2016; **45**: 82-9.

13. Tekgunduz E, Sencan I, Kapuagasi A, Unal D, Ozturk M, Gumus E, Goker H, Tavit EB, Ertem M, Cetin M, Arat M, Soysal T, Karakasli O, Sur HY, Yesilipek A, **Ferhanoglu B**, Uckan D, Ilhan O, Altuntas F. **Hematopoietic cell transplantation activity of Turkey in 2014: Ongoing increase in HCT rates.** Transfus Apher Sci. 2016.

14. Tanrikulu Simsek E, Eskazan AE, Cengiz M, Ar MC, Ekizoglu S, Salihoglu A, Gulturk E, Elverdi T, Ongoren Aydin S, Senem Demiroz A, Buyru AN, Baslar Z, Ozbek U, **Ferhanoglu B**, Aydin Y, Tuzuner N, Soysal T. **Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.** J Clin Pathol. 2016.

15. Yemisen M, Balkan, II, Salihoglu A, Eskazan AE, Mete B, Ar MC, Ongoren S, Baslar Z, Ozaras R, Saltoglu N, Mert A, **Ferhanoglu B**, Ozturk R, Tabak F, Soysal T. **The Changing Epidemiology of Blood Stream Infections and Resistance in Haematopoietic Stem Cell Transplantation Recipients.** Turk J Haematol. 2015.

16. Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, **Ferhanoglu B.** **Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.** Ann Hematol. 2015; **94**(3): 415-20.

17. Ozturk E, Ozbalak M, Berk S, Erdogan I, Avsar E, Dolgun A, Cetiner M, Mandel NM, Yalniz FF, Elverdi T, Salihoglu A, Eskazan AE, Ar MC, Ongoren S, Baslar Z, Aydin Y, Soysal T, **Ferhanoglu B.** **Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.** Leuk Lymphoma. 2015: 1-4.

18. Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, **Ferhanoglu B.** **Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.** Blood. 2015; **126**(16): 1893-901.

19. Islak Mutcali S, Saltoglu N, Balkan, II, Ozaras R, Yemisen M, Mete B, Tabak F, Mert A, Ozturk R, Ongoren S, Baslar Z, Aydin Y, **Ferhanoglu B**, Soysal T. **Early Changes of Mannose Binding Lectin, H-ficolin and Procalcitonin in Patients With Febrile Neutropenia: A Prospective, Observational Study.** Turk J Haematol. 2015.

20. Demirel A, Tabak F, Ar MC, Mete B, Ongoren S, Yemisen M, Ozaras R, Eskazan AE, Baslar Z, Mert A, Soysal T, **Ferhanoglu B**, Aydin Y, Ozturk R. **Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.** Turk J Haematol. 2015.

21. Aydin SO, Eskazan AE, Berk S, Erdogan I, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Baslar Z, Soysal T, **Ferhanoglu B**, Tuzuner N, Aydin Y. **Retrospective Evaluation of 83 Patients with Hairy**



**Cell Leukemia Treated with 3 Different Treatment Modalities in the Last Two Decades: A Single Center Experience.** *Haematologica.* 2015; **100**: 424-5.

22. Tokmak H, Ergonul O, Demirkol O, Cetiner M, **Ferhanoglu B.** **Diagnostic contribution of (18)F-FDG-PET/CT in fever of unknown origin.** *Int J Infect Dis.* 2014; **19**: 53-8.

23. Soysal T, Salihoglu A, Esatoglu SN, Gulturk E, Eskazan AE, Hatemi G, Hatemi I, Aydin SO, Erzin YZ, Baslar Z, Tuzuner N, **Ferhanoglu B,** Celik AF. **Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature.** *Rheumatology.* 2014; **53**(6): 1136-41.

24. **Ferhanoglu B,** Salihoglu A, Elverdi T, Karadogan I, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin A, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Paydas S. **Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey.** *Haematologica.* 2014; **99**: 675-6.

25. Eskazan AE, Eyice D, Kurt EA, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, **Ferhanoglu B,** Aydin Y, Tuzuner N, Ozbek U, Soysal T. **Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.** *Leuk Res.* 2014; **38**(7): 781-7.

26. Cetin G, Eskazan AE, Ar MC, Aydin SO, **Ferhanoglu B,** Soysal T, Baslar Z, Aydin Y. **Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.** *Turk J Haematol.* 2014; **31**(4): 374-80.

27. Berk S, Ozgur N, Yalniz FF, Elverdi T, Salihoglu A, Eskazan AE, Ar MC, Baslar Z, Soysal T, **Ferhanoglu B,** Tuzuner N, Aydin Y, Aydin SO. **Primary Gastrointestinal Non-Hodgkin's Lymphoma: Retrospective Evaluation of 50 Patients.** *Haematologica.* 2014; **99**: 694-.

28. Ardeshtna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, **Ferhanoglu B,** Bradstock K, Linch DC. **Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.** *Lancet Oncol.* 2014; **15**(4): 424-35.

29. Yilmaz M, Eskazan AE, Unsal A, Taninmis H, Kara E, Cetiner M, **Ferhanoglu B.** **Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature.** *Transfusion.* 2013; **53**(7): 1586-93.

30. Tokmak H, Ergonul O, Demirkol O, Cetiner M, **Ferhanoglu B.** **Diagnostic Contribution of F-18 FDG-PET/CT on the Management of FUO.** *Eur J Nucl Med Mol I.* 2013; **40**: S138-S.

31. Salihoglu A, Ozbalak M, Keskin D, Tecimer T, Soysal T, **Ferhanoglu B.** **An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.** *Transplant Proc.* 2013; **45**(7): 2845-8.

32. Salihoglu A, Hatemi I, Senel TE, Aki H, **Ferhanoglu B.** **Massive gastrointestinal bleeding during the course of chronic myelomonocytic leukemia.** *J Gastrointestin Liver Dis.* 2013; **22**(1): 7.

33. Sahin F, Saydam G, Comert M, Uz B, Yavuz AS, Turan E, Yonal I, Atay H, Keltikli E, Turgut M, Pehlivan M, Akay MO, Gurkan E, Paydas S, Kahraman S, Demirkan F, Kirkizlar O, Akpinar S, Pamuk GE, Demir M, Ozbas HM, Sonmez M, Gulturk M, Salihoglu A, Eskazan AE, Ar C, Haydaroglu Sahin H, Ongoren S, Baslar Z, Aydin Y, Yenere MN, Tuzuner N, **Ferhanoglu B**, Haznedaroglu IC, Ilhan O, Soysal T. **Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients**. Turk J Haematol. 2013; **30**(4): 351-8.
34. Ozbalak M, Tokatli I, Ozdemirli M, Tecimer T, Ar MC, Ornek S, Koroglu A, Laleli Y, **Ferhanoglu B**. **Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient**. Eur J Haematol. 2013; **91**(5): 467-9.
35. Ozbalak M, Ar MC, Tuzuner N, Salihoglu A, Eskazan AE, Ongoren Aydin S, Baslar Z, Soysal T, Aydin Y, Barak Dolgun A, Ergonul O, **Ferhanoglu B**. **Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study**. ISRN Hematol. 2013; **2013**: 908191.
36. Erbilgin Y, Eskazan AE, Ng OH, Salihoglu A, Elverdi T, Firtina S, Tatonyan SC, Aydin SO, Ar MC, Baslar Z, Sayitoglu M, **Ferhanoglu AB**, Aydin Y, Ozbek U, Soysal T. **Next-Generation Sequencing Of The BCR-ABL1 Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance**. Blood. 2013; **122**(21).
37. Aki H, Uzunaslana D, Saygin C, Demir H, Salihoglu A, **Ferhanoglu B**, Tuzuner N. **Clinicopathologic features of primary thyroid lymphomas: A single center experience**. Virchows Arch. 2013; **463**(2): 151-.
38. Selcukbiricik F, Tural D, Elicin O, Berk S, Ozguroglu M, Bese N, **Ferhanoglu B**. **Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease**. ISRN Oncol. 2012; **2012**: 951816.
39. **Ferhanoglu B**, Ozbalak M. **Diffüz Büyük B Hücreli Lenfoma (Article published in Turkish, Title: Diffuse Large B Cell Lymphoma)**. HematoLog-Special Issue on Lymphoma. 2013; **3**(2): 355-81.
40. **Ferhanoglu B**, Ozbalak M. **Primer Merkezi Sinir Sistemi Lenfomaları (Article published in Turkish, Title: Primary Central Nervous System Lymphomas)**. HematoLog-Special Issue on Lymphoma. 2013; **3**(2): 382-94.
41. Ozturk M, Ozaydin S, Oyan B, Ozbalak M, Arpacı F, Paydas S, Ataergin S, **Ferhanoglu B**, Kocak N, Gurkan E, Ozet A, Barista I. **The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis**. J Clin Oncol. 2012; **30**(15).
42. Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A, Tuzuner N, **Ferhanoglu B**. **Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience**. Hematol Oncol. 2012; **30**(2): 76-81.

43. Ari MC, Buyuktas D, Eskazan AE, Ongoren Aydin S, Tanrikulu E, Baslar Z, Buyru AN, **Ferhanoglu B**, Aydin Y, Tuzuner N, Soysal T. **The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.** Turk J Haematol. 2012; **29**(3): 242-7.
44. Offner F, **Ferhanoglu B**, Reeves JA, Eom HS, Doner K, Raposo J, Flinn IW, Suh C, Chowhan NM, Prasad S, Kussick SJ, Mulligan G, Rizo A, Leonard JP. **Phase 2 Studies of Immunochemotherapy +/- Bortezomib (Vc) in Newly Diagnosed Non-Germinal Center B-Cell-Like (Gcb) Dlbcl: Rapid Prospective Identification of Non-Gcb Patients (Pts).** Ann Oncol. 2011; **22**: 225-.
45. Leonard J, Reeves J, **Ferhanoglu B**, Doner KT, Eom H, Flinn IW, Raposo J, Chowhan NM, Suh C, Noga S, Tumyan G, Aung S, Hajdenberg J, Ulrich BK, Pendergrass KB, Mulligan G, Rizo A, Kussick S, Offner F. **PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification.** J Clin Oncol. 2011; **29**(15).
46. Eskazan AE, Tatonyan SC, Salihoglu A, Gulturk E, Ar MC, Aydin SO, Baslar Z, **Ferhanoglu AB**, Tuzuner N, Aydin Y, Ozbek U, Soysal T. **Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia.** Blood. 2011; **118**(21): 736-.
47. Eskazan AE, Soysal T, Ongoren S, Gulturk E, **Ferhanoglu B**, Aydin Y. **Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.** Haematologica. 2011; **96**(3): e15; author reply e6-7.
48. Eskazan AE, Soysal T, Erbilgin Y, Ozbek U, **Ferhanoglu B**. **Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?** Leuk Res. 2011; **35**(9): e145-6.
49. Eskazan AE, Ongoren S, Ar MC, Soysal T, **Ferhanoglu B**, Aki H, Aydin Y. **Essential thrombocythemia and multiple myeloma: two rare diseases in one patient.** Clin Lymphoma Myeloma Leuk. 2011; **11**(5): 442-5.
50. Eskazan AE, Akmurad H, Ongoren S, Ozer O, **Ferhanoglu B**. **Primary gastrointestinal diffuse large B cell lymphoma presenting with cold agglutinin disease.** Case Rep Gastroenterol. 2011; **5**(2): 262-6.
51. Arslan F, Tabak F, Avsar E, Midilli K, Mert A, Ozaras R, Soysal T, Ozturk R, **Ferhanoglu B**. **Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient.** J Neurovirol. 2010; **16**(2): 174-8.
52. Ardeshtna KM, Qian WD, Smith P, Warden J, Stevens L, Pocock CFE, Miall F, Cunningham D, Davies J, Walewski J, **Ferhanoglu AB**, Bradstock K, Linch DC. **An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic,**

**Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis.** Blood. 2010; **116**(21): 5-.

53. Ure U, Ar MC, Baslar Z, Soysal T, Ongoren S, Gulseven M, Aydin Y, Ulku B, Tuzuner N, **Ferhanoglu B. The Effect of ZAP-70 Expression on Disease Progression in Early-Stage (Binet A) B-CLL Patients.** Trak Univ Tip Fak De. 2009; **26**(4): 317-21.

54. Tarkan-Arguden Y, Ar MC, Yilmaz S, Ongoren S, Kuru D, Ure U, Cirakoglu A, Eskazan AE, Guven GS, Cetin G, Purisa S, Baslar Z, Deviren A, Aydin Y, Hacıhanefioglu S, **Ferhanoglu B, Tuzuner N, Ulku B, Soysal T. Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia.** Biotechnol Biotec Eq. 2009; **23**(4): 1515-20.

55. Saydam G, Haznedaroglu IC, Temiz Y, Soysal T, Sucak G, Tombuloglu M, Ozdogu H, Yavuz S, Altintas A, Ozet G, Gulbas Z, **Ferhanoglu B, Ilhan O. Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months.** Uhod-Uluslar Hematol. 2009; **19**(4): 195-204.

56. Ozer O, Eskazan AE, Ar MC, Bekoz H, Tabak F, Ongen G, **Ferhanoglu B. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports.** J Med Case Rep. 2009; **3**: 7306.

57. Ongoren S, Tarkan-Arguden Y, Ar MC, Yilmaz S, Ure U, Kuru D, Eskazan AE, Guven GS, Cetin G, Cirakoglu A, Baslar Z, Deviren A, Aydin Y, Hacıhanefioglu S, **Ferhanoglu B, Tuzuner N, Ulku B, Soysal T. Clonal Chromosomal Abnormalities in Philadelphia-Negative Cells and Their Clinical Significance in Patients with Chronic Myeloid Leukemia: Results of a Single Center.** Turk Klin Tip Bilim. 2009; **29**(2): 321-30.

58. Ar MC, Ozbalak M, Tuzuner N, Bekoz H, Ozer O, Ugurlu K, Tabak F, **Ferhanoglu B. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases.** Transplant Proc. 2009; **41**(5): 1648-53.

59. Igdem S, Okkan S, Unalan B, Igdem A, **Ferhanoglu B. Cervical cancer coexisting with small lymphocytic lymphoma detected during positron emission tomography/computed tomography simulation: a case report.** Eur J Gynaecol Oncol. 2008; **29**(4): 405-7.

60. Erdogan EB, Guner SI, Sonmezoglu K, **Ferhanoglu B, Halac M, Uslu I. Can post-treatment PET/CT scanning after first-line chemotherapy predict the prognosis in patients with Hodgkin disease and high-grade nonHodgkin lymphoma?** Eur J Nucl Med Mol I. 2008; **35**: S221-S.

61. Ure UB, Ar MC, Salihoglu A, Guner SI, Baran A, Oguz O, **Ferhanoglu B. Alemtuzumab in Sezary syndrome: efficient but not innocent.** Eur J Dermatol. 2007; **17**(6): 525-9.

62. Üre Ü, Özer Ö, Beköz H, Tüzüner N, **Ferhanoglu B. İmages 96: Hodgkin Lymphoma Presenting as a Palpable Scalp Mass.** Bloodmed. 2007.

63. Soer M, Ozbalak M, Senocak M, Soysal T, **Ferhanoglu B, Molinas N, Tuzuner N. Prognostic significance of micro vessel density in diffuse large B cell lymphomas.** Virchows Arch. 2007; **451**(2): 357-8.

64. Sili U, Yilmaz M, **Ferhanoglu B**, Mert A. **Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole**. Clin Infect Dis. 2007; **45**(7): 897-8.
65. Ozer O, Eskazan E, Bekoz H, Peker K, Yuksel S, Altiok E, **Ferhanoglu B**. **A case of V617F(+) myelodysplastic/myeloproliferative disorder**. Virchows Arch. 2007; **451**(2): 434-.
66. Hatirnaz O, Ure U, Ar C, Akyerli C, Soysal T, **Ferhanoglu B**, Ozcelik T, Ozbek U. **The SOCS-1 gene methylation in chronic myeloid leukemia patients**. Am J Hematol. 2007; **82**(8): 729-30.
67. Hatirnaz O, Ekmekci CG, Ar C, Ure U, Soysal T, **Ferhanoglu B**, Ozbek U. **Detection of SOCS-1 (suppressor of cytokine signaling-1) methylation in CML (chronic myeloid leukemia) patients**. Febs J. 2006; **273**: 322-.
68. Pamuk ON, Pamuk GE, Soysal T, Ongoren S, Baslar Z, **Ferhanoglu B**, Aydin Y, Ulku B, Aktuglu G, Akman N. **Chronic lymphocytic leukemia in Turkey: experience of a single center in Istanbul**. South Med J. 2004; **97**(3): 240-5.
69. Aki H, Tuzuner N, Ongoren S, Baslar Z, Soysal T, **Ferhanoglu B**, Sahinler I, Aydin Y, Ulku B, Aktuglu G. **T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma**. Leuk Res. 2004; **28**(3): 229-36.
70. Gurses N, Kalayoglu-Besisik S, Sargin D, **Ferhanoglu B**, Anak S, Soysal T, Baslar Z, Ongoren S, Bilgen H, Gedykoglu G, Aydin M, Abacy N, Gul A, Ozbek U. **Interleukin-6 gene polymorphisms associate with acute graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation**. Bone Marrow Transpl. 2003; **31**: S129-S.
71. **Ferhanoglu B**, Ongoren S, Ar CM, Uzel B, Forta H, Necioglu D. **Intrathecal methotrexate-induced acute cerebellar syndrome**. Ann Hematol. 2003; **82**(4): 241-3.
72. Akan H, Uzun O, Akova M, Senol E, Ozkalemkas F, **Ferhanoglu B**, Dincer S, Korten V. **FUNGOBASE: An epidemiological study to determine the trends in antifungal treatment in Turkey**. Trends in Medical Mycology. 2003: 43-7.
73. Tiryakioglu O, Kadioglu P, Ongoren S, Acbay O, **Ferhanoglu B**, Gundoglu S, Korugan U. **An unusual cause of hypercalcemia in polycythemia vera: parathyroid adenoma**. Acta Med Okayama. 2002; **56**(3): 167-70.
74. Pamuk GE, Pamuk ON, Soysal T, Ongoren S, Baslar Z, **Ferhanoglu B**, Aydin Y, Ulku B, Aktuglu G, Akman N. **An overview of young CLL patients: a single-centre experience from Turkey**. Haematologia. 2002; **31**(4): 303-11.
75. Pamuk GE, Pamuk ON, Baslar Z, Ongoren S, Soysal T, **Ferhanoglu B**, Aydin Y, Ulku B, Aktuglu G, Akman N. **Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy**. Ann Hematol. 2002; **81**(8): 436-40.
76. Ozbek U, Gurses N, Kalayoglu-Besisik S, Aydin M, Bilgen H, Ongoren S, Yalman N, Anak S, Baslar Z, Soysal T, **Ferhanoglu B**, Gedikoglu G, Sargin D. **The value of TNF-alpha and IL-10 gene**

**polymorphisms in the incidence and severity of graft-versus-host disease.** Bone Marrow Transpl. 2002; **29**: S198-S.

77. Ozbek U, Gurses N, Kalayoglu-Besisik S, Aydin M, Bilgen H, Ongoren S, Yalman N, Abaci N, Anak S, Baslar Z, Soysal T, Gul A, **Ferhanoglu B**, Aydin Y, Ulku B, Aktuglu G, Gedikoglu G, Sargin D. **Cytokine gene polymorphism in patients with graft-versus-host disease after HLA-matched bone marrow transplantation.** Blood. 2001; **98**(11): 361b-b.

78. **Ferhanoglu AB**, Acicbe O, Ongoren S, Tabak F, Baslar Z, Ozturk R, Soysal T, Mert A, Yilmaz M, Murtezaoglu A, Aydin Y, Ulku B, Aktuglu G, Aktuglu Y. **Profile of microorganisms isolated from febrile neutropenic patients.** Blood. 2001; **98**(11): 26b-b.

79. Erman M, Akova M, Akan H, Kortten V, **Ferhanoglu B**, Koksali I, Cetinkaya Y, Uzun O, Unal S. **Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.** Scand J Infect Dis. 2001; **33**(11): 827-31.

80. Soysal T, Pamuk ON, Pamuk GE, Ongoren S, Baslar Z, **Ferhanoglu B**, Aydin Y, Ulku B, Aktuglu G, Akman N. **An overview of young CLL patients.** Blood. 2000; **96**(11): 294b-b.

81. Pamuk GE, Pamuk ON, Baslar Z, Ongoren S, Soysal T, **Ferhanoglu B**, Aydin Y, Ulku B, Aktuglu G, Akman N. **A single center experience with 321 ITP patients.** Blood. 2000; **96**(11): 68b-9b.

82. Giles FJ, Shan J, Advani SH, Akan H, Aydogdu I, Aziz Z, Azim HA, Bapsy PP, Buyukkececi F, Chaimongkol B, Chen PM, Cheong SK, **Ferhanoglu B**, Hamza R, Khalid HM, Intragumtornchai T, Kim SW, Kim SY, Koc H, Kumar L, Kumar R, Lei KI, Lekhakula A, Muthalib A, Patel M, Poovalingam VP, Prayoonwiwat W, Rana F, Reksodiputro AH, Ruff P, Sagar TG, Schwarzer AP, Song HS, Suh CW, Suharti C, Supindiman I, Tee GY, Thamprasit T, Villalon AH, Wickham NR, Wong JE, Yalcin A, Jootar S. **A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study.** Leuk Lymphoma. 2000; **40**(1-2): 95-103.

83. Demircioglu M, Ongoren S, Uzel B, Karadogan I, Aky H, Tuzuner N, Undar L, **Ferhanoglu B**. **Comparison of flow cytometry with other methods in diagnosis of PNH.** Blood. 2000; **96**(11): 10b-b.

84. Budak T, Besisik S, Akan H, Baslar Z, Ratip S, Koc H, **Ferhanoglu B**, Bayik M, Tangun Y. **The prevalence of tuberculosis (TBC) in adult allogeneic stem cell transplant recipients in Turkey.** Bone Marrow Transpl. 1999; **23**: S123-S.

85. Baslar Z, Ongoren S, Soysal T, **Ferhanoglu B**, Aktuglu G, Ulkii B. **Extramedullary relapse after allogeneic stem cell transplantation.** Bone Marrow Transpl. 1999; **23**: S2-S.

86. Aydingoz IE, **Ferhanoglu B**, Guney O. **Does tissue iron status have a role in female alopecia?** J Eur Acad Dermatol Venereol. 1999; **13**(1): 65-7.

87. Ulutin ON, Ulutin ŞB, Çizmeçi G, T U, **Ferhanoglu B. Some Clinical, Pharmacological Observations of the Effect of Defibrotide in Human.** Acta Pharmaceutica Turcica. 1998; (30): 57-62.
88. Soysal T, Baslar Z, **Ferhanoglu B**, Akman N. **Donor leukocyte infusions for acute myeloid leukemia relapsing after stem cell transplantation.** Acta Haematol. 1998; **99**(1): 49-51.
89. Baslar Z, Soysal T, Aygun G, **Ferhanoglu B**, Sarioglu AC, Ulku B. **Successfully treated invasive central nervous system aspergillosis in an allogeneic stem cell transplant recipient.** Bone Marrow Transpl. 1998; **22**(4): 404-5.
90. Ozen S, **Ferhanoglu B**, Senocak M, Tuzuner N. **Idiopathic myelofibrosis (agnogenic myeloid metaplasia): clinicopathological analysis of 32 patients.** Leuk Res. 1997; **21**(2): 125-31.
91. Ozbek U, Vural B, Kalayoglu S, Soysal T, Bilgen H, Yavuz S, Anak S, Sargin D, Gedikoglu G, **Ferhanoglu B**, Akoglu T, Tangun Y, Ozcelik T. **Evaluation of chimerism with DNA polymorphisms in bone marrow transplantation.** Turk J Pediatr. 1997; **39**(3): 303-11.
92. **Ferhanoglu B**, Erzin Y, Baslar Z, Tuzuner HA. **Secondary amyloidosis in the course of idiopathic myelofibrosis.** Leuk Res. 1997; **21**(9): 897-8.
93. Baslar Z, Soysal T, Hanci M, Aygun G, **Ferhanoglu B**, Sarioglu AC, Ulku B. **Successful outcome of aspergillus brain abscess in a patient who underwent bone marrow transplantation for aplastic anemia.** Haematologia. 1997; **28**(4): 265-71.
94. Başlar Z, Tüfekçi IB, Soysal T, **Ferhanoglu B**, Aydın Y, Aktuğlu G, Akman N , B Ü. **Neutropenic Enterocolitis In Acute Leukemia.** Turkish Journal Of Haematology. 1997; (14): 109-12.
95. Ulutin ON, Balkuv-Ulutin S, Bezer-Goker B, Cizmeçi G, **Ferhanoglu B**, Ozsoy Y, Ugur MS, Ulutin T, Yaman A, Yardimci T. **Effect of defibrotide on platelet function.** Semin Thromb Hemost. 1996; **22 Suppl 1**: 21-4.
96. Sayman HB, Sonmezoglu K, Altioek E, Devranoglu G, **Ferhanoglu B. Unexpected bone marrow uptake of thallium-201 in nonsecretory myeloma.** J Nucl Med. 1995; **36**(2): 250-1.
97. Soysal T, **Ferhanoglu B**, Bilir M, Akman N. **Oculomotor nerve palsy associated with vincristine treatment.** Acta Haematol. 1993; **90**(4): 209-10.
98. Ertugrul H, Aydemir A, **Ferhanoglu B**, Oğuz O, Akçakaya N, Tozakı S, Avanoglu Y, Y G. **Hyper IgE Syndrome Amiloidosis and Developmental Defect.** Turkish Journal of Medical and Biological Research. 1992; (3): 305-9.
99. Wu KK, Sanduja R, Tsai AL, **Ferhanoglu B**, Loose-Mitchell DS. **Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells.** Proc Natl Acad Sci U S A. 1991; **88**(6): 2384-7.
100. Ulutin ON, Ulutin SB, Ugur MS, Ulutin T, Erbençi T, **Ferhanoglu B**, T Y. Defibrotide and its Effects on Platelet Function. In: Thrombosis and Haemorrhagic Disorders. In: Vinazzer HSaH, ed. Schimmitt and Meyer GmBH Winzburg; 1989. p. 426-28.
101. Ulutin ON, Ulutin SB, Çizmeçi G, T U, **Ferhanoglu B. Some Clinical, Pharmacological Observations of the Effect of Defibrotide in Human.** Acta Pharmaceutica Turcica. 1988; (30): 57-62.

## Uluslararası Konferans Sunumları:

- 1. Burhan Ferhanoglu**, Murat Özbalak, Hüseyin Beköz, Nuri Karadurmuş, Semra Paydaş, Alev Türker, Tayfur Toptaş, Tülin Fıratlı Tuğlular, Mehmet Sönmez, Zafer Gülbaş, Nazlı Demir, Leylagül Kaynar, Rahşan Yıldırım, İhsan Karadoğan, Mutlu Arat, Funda Pepedil Tanrikulu, Vildan Özkocaman, Hüseyin Abalı, Mehmet Turgut, Meltem Kurt Yüksel, Muhit Özcan, Sibel Kabukçu Hacıoğlu, İbrahim Barışta, Metin Demirkaya, Fatoş Dilan Köseoğlu, Selami K. Toprak, Mehmet Yılmaz **Nivolumab for relapsed or refractory Hodgkin lymphoma: real life experience** EHA24, 24th International Congress of European Hematology Association, Poster Session, Abstract No:P1245, June 13-16, 2019, Amsterdam, Netherlands
- 2. Burhan Ferhanoglu**, Tae Min Kim, Gayane Tumyan, Su-Peng Yeh, David Brittain, Amado Karduss, Yok Lam Kwong, Soon Thye Lim, Mubarak Al Mansour, Silvia Rivas-Vera, Yuqin Song, Marta Zerga, Julie Blair, Mehul Dalal, Hui Wan, Mark Hertzberg **Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC)** Poster Session in 60th Annual Meeting of American Society of Hematology, San Diego, December 1-4, 2018
- 3. Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, A. Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch Albareda, María Dolores Caballero Barrigón, Aisha Masood, Michael Streit, John Alvarez, Rob Ceulemans, Behzad Kharabi Masouleh, Sriram Balasubramanian, Michael Schaffer, Shean-Sheng Wang, Nele Fourneau, and Wojciech Jurczak. “Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia”** Oral Session in 59th Annual Meeting of American Society of Hematology, Atlanta, December 9-12, 2017
- 4. Ferhanoglu B, Beköz H, Karadurmuş N, Paydaş S, Türker A, Toptaş T, Fıratlı Tuğlular T, Sönmez M, Gülbaş Z, Özbalak M; “Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Real-Life Experience”** Poster Session in 4th Aegean Hematology Oncology Symposium”, Rhodes, Greece, September 21-24, 2017



5. **Ferhanoğlu B**, Bekoz H, Karadurmus N, Paydas S, Turker A, Toptas T, Firatli Tuğlular T, Sonmez M, Gulbas Z, Tekgunduz E, Kaya AH, Ozbalak M, Tastemir N, Kaynar L, Yildirim R, Karadogan I, Arat M, Pepedil Tanrikulu F, Ozkocaman V, Abali H, Turgut M, Kurt Yuksel M, Ozcan M, Dogu MH, Kabukcu Hacıoglu S, Barista I, Demirkaya M, Koseoglu FD, Toprak SK, Yilmaz M. **Nivolumab for relapsed or refractory Hodgkin lymphoma: Experience in Turkey** EHA22, 22nd International Congress of European Hematology Association, Poster Session, Abstract No:P281, June 22-25, 2017, Madrid, Spain
6. **Ferhanoğlu B**, Öztürk E, Berk S, Erdoğan I, Özbalak M, Avşar E, Dolgun A, Çetiner M, Molinas N, Yalnız FF, Elverdi T, Salihoğlu A, Eşkazan AE, Ar MC, Aydın Ş, Başlar Z, Aydın Y, Soysal T **COMPARISON OF IPI AND NCCN-IPI IN 324 DE NOVO DLBCL PATIENTS: MULTICENTER RETROSPECTIVE ANALYSIS** 13-ICML, 13th International Conference on Malignant Lymphoma, Poster Session, Abstract No:357, Palazzo dei Congressi, Lugano (Switzerland), 17-20 June, 2015
7. Erbilgin Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, Elverdi T, Firtina S Catal Tatonyan S, Ongoren Aydin S, Ar MC, Baslar Z, Sayitoglu M, **Ferhanoglu B**, Aydin Y, Ozbek U, Soysal T **Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance.** *53rd ASH Annual Meeting and Exposition, Oral Session, Abstract No:384*, December 7-10, 2013, Louisiana, New Orleans, USA.
8. Offner F, Samoilova O, Osmanov E, Eom H, Topp M, Raposo J, Pavlov V, Ricci D, Zhu E, Velde H.van de, Enny C, Rizo A, **Ferhanoglu B**. **PHASE 2 STUDY OF RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE WITH BORTEZOMIB (VCR-CAP) OR VINCRISTINE (R-CHOP) IN PATIENTS WITH NEWLY DIAGNOSED NON-GERMINAL CENTRE B-CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA** Special Issue: 12th International Conference on Malignant Lymphoma, Poster Session, Abstract No:214, Palazzo dei Congressi, Lugano, Switzerland, June 19–22, 2013
9. Murat OZBALAK, M. Cem AR, Nükhet TUZUNER, Ayşe SALIHOGLU, A. Emre ESKAZAN, Şeniz Ongoren AYDIN, Zafer BASLAR, Teoman SOYSAL, Yildiz AYDIN, Anıl Barak DOLGUN, Onder ERGONUL & **Burhan FERHANOGLU**. 2013. **Detailed analysis of diffuse large B cell lymphoma patients: A single center, retrospective study reporting on young patients.- Poster Presentation** In *4th International Congress of Leukemia-Lymphoma-Myeloma*. Istanbul.
10. Murat OZBALAK, Ilyas Tokatlı, Metin Özdemirli, Tulay Tecimer, M. Cem Ar, Serdar Örnek, Aykut Koroglu, Yahya Laleli & **Burhan Ferhanoglu**. 2013b. **IS VALGANCICLOVIR REALLY EFFECTIVE IN PRIMARY EFFUSION LYMPHOMA?: CASE REPORT OF AN HIV(-) EBV(-) HHV8(+) PATIENT.** Poster

Presentation: In *4th International Congress of Leukemia-Lymphoma-Myeloma*. Istanbul, Turkey

**11.** Cagatay KUNDAK, Murat OZBALAK, Serdar ORNEK, **Burhan FERHANOGLU** & Yahya Rauf LALELİ. 2013. **RECOGNITION OF IMMUNOGLOBULIN D MULTIPLE MYELOMA CASE REPORT AND SHORT REVIEW**. Poster Presentation: In *4th International Congress of Leukemia-Lymphoma-Myeloma*. Istanbul, Turkey.

**12.** Ozturk M, Ozaydin S, Oyan B, Ozbalak M, Arpaci F, Paydas S, Ataergin S, **Ferhanoglu B**, Kocak N, Gurkan E, Ozet A, Barista I; **The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis**, *ASCO 48th Annual Meeting 2012*, June 1–5, 2012, Chicago, Illinois, USA.

**13.** Leonard J, Reeves J, **Ferhanoglu B**, Doner KT, Eom H, Flinn IW, Raposo J, Chowhan NM, Suh C, Noga S, Tumyan G, Aung S, Hajdenberg J, Ulrich BK, Pendergrass KB, Mulligan G, Rizo A, Kussick S, Offner F; **PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification**, *ASCO 47th Annual Meeting 2011*, June 3–7, 2011, Chicago, Illinois, USA.

**14.** Ardeshtna KM, Smith P, Qian W, Warden J, Stevens L, Pocock CFE, Miall F, Cunningham D, Davies J, Jack A, Walewski J, **Ferhanoglu B**, Bradstock K and Linch DC; **An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a)**, A Preliminary Analysis., *53rd ASH Annual Meeting and Exposition, Plenary Scientific Session (6th from among 5,493 abstract submissions)*, December 10-13, 2011, San Diego, CA, USA.

**15.** Eskazan AE, Tatonyan SC, Salihoglu A, Gulturk E, Ar MC, Ongoren Aydin S, Baslar Z, **Ferhanoglu B**, Tuzuner N, Aydin Y, Ozbek U, Soysal T : Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia. *53rd ASH Annual Meeting and Exposition, Poster Session, Abstract No:1692*, December 10-13, 2011, San Diego, CA, USA.

**16.** **Ferhanoglu B; Non-Hodgkin lymphoma – Clinical**, 16th Congress of EHA: June 9 - 12, 2011, Excel London, United Kingdom.

17. **Ferhanoglu B; DLBCL First Line Treatment**, *3rd International Congress on Lymphoma- Leukemia- Myeloma (LLM) Congres*, Turkish Society of Hematology, 11-14 May 2011, İstanbul, TURKEY.
18. **Ferhanoglu B; DLBCL First Line Treatment**, *1th International Lymphoma- Leukemia- Myeloma (LLM) Congres*, Turkish Society of Hematology, Fethiye, 24- 27 May 2007.
19. Hatırnaz O, Ekmekçi CG, Ar MC, Üre Ü, Soysal T, **Ferhanoğlu B, Özbek Ö; Detection of SOCS-1 (Suppressor of Cytokine Signaling-1) Methylation in CML (Chronic Myeloid Leukemia) Patients**, *Febs Journal*; 273: 322-322 pp915 Suppl. 1, Jun 2006.
20. Gürses N, Kalaycıoğlu- Beşışık S, Sargın D, **Ferhanoğlu B**, Anak S, Soysal T, Başlar Z, Öngören Ş, Bilgen H, Gedikoğlu G, Aydın M, Abacı N, Gül A, Özbek Ü **Interleukin-6 Gene Polymorphisms Associate with Acute Graft-versus-Host Disease in HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation**. *Bone Marrow Transplantation*; 31: S129- S129 Suppl. 1, Mar 2003.
21. Özbek Ü, Gürses N, Kalayoğlu- Beşışık S, Aydın M, Bilgen H, Öngören Ş, Yalman N, Anak S, Başlar Z, Soysal T, **Ferhanoğlu B**, Gedikoğlu G, Sargın D; **The Value of TNF-Alpha and IL-10 Gene Polymorphisms in the Incidence and Severity of Graft-versus-Host Disease**, *Bone Marrow Transplantation*; 29: 198- 198 Suppl. 2 Mar 2002.
22. Özbek Ü, Gürses N, Kalayoğlu- Beşışık S, Aydın M, Bilgen H, Öngören Ş, Yalman N, Abacı N, Anak S, Başlar Z, Soysal T, Gül A, **Ferhanoğlu B**, Aydın Y, Ülkü B, Aktuğlu G, Gedikoğlu G, Sargın D; **Cytokine Gene Polymorphisms in Patients with Graft-versus-Host Disease After HLA-matched Bone Marrow Transplantation**, *Blood*; 98 (11): 5216 part 2, Nov 2001.
23. Demircioğlu M, Öngören Ş, Uzel B, Karadoğan I, Akı H, Tüzüner N, Undal L, **Ferhanoğlu B; Comparison of Flow Cytometry with Other Methods in Diagnosis of PNH**, *Blood*; 96(11): 3696 Part 2, Nov 2000.
24. Pamuk GE, Pamuk ON, Başlar Z, Öngören Ş, Soysal T, Ferhanoğlu B, Aydın Y, Ülkü B, Aktuğlu G, Akman N; **A Single Center Experience with 321 ITP Patients**, *Blood*; 96(11): 3970 Part 2, Nov 2000.
25. Başlar Z, Öngören Ş, Soysal T, **Ferhanoğlu B**, Aktuğlu G, Ülkü B; **Extramedullary Relapse After Allogeneic Stem Cell Transplantation**, *25th Annual Meeting of the EBMT and 15th Meeting of the Nurses Group*, Hamburg, 21- 25 Mar 1999.

26. Başlar Z, Öngören Ş, Soysal T, **Ferhanoğlu B**, Aktuğlu G, Ülkü B; **Extrameullary Relapse After Allogeneic Stem Cell Transplantation**, *Bone Marrow Transplantation*; 23: 4 Suppl., Mar 1999.
27. Budak T, Beşışık S, Akan H, Başlar Z, Ratip S, Koç H, **Ferhanoğlu B**, Bayık M, Taygun Y; **The Prevalance of Tuberculosis (TBC) in Adult Allogenic Stem Cell Transplant Recipients in Turkey**, *Bone Marrow Transplantation*; 23: 404 Suppl., Mar 1999.
28. Aydın F, Oğuz FS, Kalayoğlu S, Başlar Z, Gürtekin M, Soysal T, Sargın D; **Ferhanoğlu B**, Çarin M; **The Relation Between HLA Antigens and GVHD in Turkish Patients Transplanted with HLA Identical Hematopoietic Stem Cell**, *23rd Annual Meeting of the EBMT and 13th Meeting of the Nurses Group*, Aix- Le Bains, 23- 27 Mar 1997.
29. Kalayoğlu S, Soysal T, Başlar Z, Yenerer MN, Yavuz AS, Sargın D, **Ferhanoğlu B**, Atamer T, Akman N, Tangün Y; **Donor Leukocyte Infusions for Acute Myeloid Leukemia (AML) Relapsing After Stem Cell Transplantation ( SCT )**, *23rd Annual Meeting of the EBMT and 13th Meeting of the Nurses Group*, Aix- Le Bains, 23- 27 Mar 1997.
30. Başlar Z, Tüfekçi BI, Soysal T , **Ferhanoğlu B**, Aydın Y, Aktuğlu G, Akman N, Ülkü B; **Neutropenic Enterocolitis In Acute Leukemia**, *Turkish Journal of Haematology* , 14: 109-112, 1997.
31. Çungurlu A, Başlar Z, Demir G, Özgüroğlu M, Soysal T, Molinas N, **Ferhanoğlu B**, Büyükünäl E, Aydın Y, Serdengeçti S, Aktuğlu G, Akman N, Ülkü B, Berkarda B; **Treatment Induced Second Neoplasms in Hodgkin's Disease**. 10th Meditteranean Congress of Chemotherapy, Antalya, 20- 25 Oct 1996.
32. Başlar Z, Aşlamacı M, Zülfikar B, Soysal T, **Ferhanoğlu B**, Aydın Y, Ülkü B, Akman N, Aktuğlu G; **Incidence of HBV, HCV, HIV Markers in Hemophilia**, XIIIth Meeting of The International Society of Hematology ( European- African Division), Istanbul, Turkey, 3- 8 Sep 1995.
33. Koç H, Akman N, Tunalı A, **Ferhanoğlu B**, Yücel I, İlhan O, Beksaç M, Aydın Y, Akan H, Özcan M, Konuk N, Aktuğlu G, Gürman G, Ülkü B; **Interferon Alfa-2b Compared to Interferon Alfa-2b Plus Chemotherapy for Remission Maintenance in Multiple Myeloma: A Multicenter Study**, XIIIth Meeting of the International Society of Hematology, Istanbul, Turkey, 3- 8 Sep 1995. Abs.No 915
34. Eralp Y, **Ferhanoğlu B**, Demir M, Hız M, Tüzüner N, Akman N, Türemen E; **Primary Lymphoma of Bone**, XIIIth Meeting of The International Society of Hematology, Istanbul, Turkey, 3- 8 Sep 1995. Abs. No 904.

35. Gürel N, Doğusoy G, **Ferhanoğlu B**, Ülkü B, Molinas N, Tüzüner N; **Immunophenotyping and DNA Flow Cytometric Analysis of Non\_Hodgkin's Lymphoma**, XIIIth Meeting of The International Society of Hematology, Istanbul, Turkey, 3- 8 Sep 1995. Abs. No 905.
36. Özen S, **Ferhanoğlu B**, Doğusoy G and Tüzüner N; **Idiopathic Myelofibrosis, Clinicopathologic Analysis of 32 Patients**, XIIIth Meeting of The International Society of Hematology, Istanbul, Turkey, 3- 8 Sep 1995. Abs. No911.
37. Başlar Z, Öngören Ş, Soysal T, **Ferhanoğlu B**, Aydın Y, Ülkü B, Aktuğlu G, Akman N; **CHOP vs M-BACOD in Agressive Non-Hodgkin's Lymphoma- Results of A Single Institution**, XIIIth Meeting of The International Society of Hematology (European- African Division), Istanbul, Turkey, 3- 8 Sep 1995.
38. Özçelik T, Özbek U, Vural B, Bilgen H, Anak S, Gedikoğlu G, Beşışık S, Sargın D, Soysal T, **Ferhanoğlu B**, Tangün Y; **Evaluation of Chimerism with DNA Polymorphisms in Bone Marrow Transplantation**, XIIIth Meeting of The International Society of Hematology (European- African Division), İstanbul, Turkey, 3- 8 September, 1995.
39. Dinçer E, Demir M, **Ferhanoğlu B**, Başlar Z, Soysal T, Aydın Y, Ülkü B, Aktuğlu G, Akman N; **Results of An Intensive Chemotherapy Protocol (BFM) in Adult ALL**, XIIIth Meeting of The International Society of Hematology (European- African Division), İstanbul, Turkey, 3- 8 Sep 1995.
40. Demir M, Başlar Z, Soysal T, **Ferhanoğlu B**, Aydın Y, Ülkü B, Aktuğlu G, Akman N; **Mitoxantrone, Etoposide, Intermediate Dose ARA-C Combination Chemotherapy Protocol in Resistant or Recurrent AML**, XIIIth Meeting of The International Society of Hematology (European- African Division) İstanbul, Turkey, 3- 8 Sep 1995.
41. **Ferhanoğlu B**, Türemen E, Demir M, Soysal T, Altınkaya N, Aksoy F, Ilıkkan B, Özkan F; **Acute Myeloblastic Leukemia in Pregnancy: A Report and Autopsy Findings of The Premature Baby**, XIIIth Meeting of The International Society of Hematology (European- African Division) İstanbul, Turkey, 3- 8 Sep 1995.
42. Tanverdi L, Soysal T, Akman N, **Ferhanoğlu B**, Eralp Y; **Moderate Dose ARA-C Induced Acute Cerebellar Syndrome**, XIIIth Meeting of The International Society of Hematology (European- African Division) İstanbul, Turkey, 3- 8 Sep 1995.
43. **Ferhanoğlu B**, Eralp Y, Arun B, Soysal T, Avanoğlu Y, Ülkü B, Aktuğlu G, Akman N, Başlar Z; **Cytokines in Multiple Myeloma**. XIIIth Meeting of The International Society of Hematology (European- African Division) İstanbul, Turkey, 3- 8 Sep 1995.

44. Arun B, Eralp Y, **Ferhanoğlu B**; **Soluble IL- 2 Receptors in Hematologic Malignancies**, XIII. Meeting of the International Society of Hematology, Istanbul, 3- 8 Sep 1995, Abs. Nb. 619.
45. **Ferhanoğlu B**, Öngen Z, Soysal T, Ali V, Aykut S, Akman N; **Fibrinogen, FVII, Apo (A) Values in Atherosclerosis Confirmed by Coronary Angiography**, XXVth Congress of The International Society of Hematology. Cancun, Mexico, 17- 22 Apr 1994.
46. **Ferhanoğlu B**, Tanrıverdi L, Akman N; **Moderetate Dose ARA-C Induced Cerebellar Toxicity**, 24th Congress of the International Society of Haematology, South Bank Centre, London, UK, 23- 27 August 1992.
47. **Ferhanoğlu B**, Soysal T, Arun B, Köymen T, Calay Z, Tüzüner N, Avanoğlu Y, Ülkü B, Aktuğlu G, Akman N; **Retrospective Analysis of 39 Myelodysplastic Cases**. 24th Congress of The International Society of Haematology. London, UK, 23- 27 Aug 1992.
48. Ulutin ON, Çizmeçi G, Özer M, Özsoy Y, Yardımcı T, Ulutin T, **Ferhanoğlu B**, Ulutin ŞB; **The Clinical and Laboratory Results of Defibrotide on the Peripheric Obliterative Vascular Diseases**, 7th European Congress of the International Union of Angiology and 3rd Mediterranean Congress of Angiology, Rhodes, Greece, p. 128, 26- 31 May 1991.
49. Wu KK, Sanduja R, Tsai AL, Loose-Mitchell DS and **Ferhanoğlu B**; **Aspirin Inhibits Interleukin 1(IL-1) Induced Prostaglandin H(PGH) Synthase Expression in Cultured Endothelial Cells**, International Society of Hematology, 23th Congress, American Society of Hematology 31th Annual Meeting, Blood, 76: Suppl 1, 2087, Nov 28- Dec 4 1990.
50. **Ferhanoğlu B** and Wu KK; **Tumor Necrosis Factor (TNF) Stimulates Endothelial Cell Prostacyclin Production by Inducing De Novo Synthesis of Prostaglandin H (PGH) Synthase (Cyclooxygenase)**, International Society of Hematology, 23th Congress, American Society of Hematology 31th Annual Meeting, Blood, 76: Suppl. 1, 2014, Boston, Nov 28- Dec 4 1990.
51. Tabak F, **Ferhanoğlu B**, Yücel A, Mamal M, Bohar H, İmeryüz N, Avanoğlu Y, Ulutin ON, Akman N; **Comparison of Piperacillin+Amikacin Versus Ceftizoxime+Amikacin Combinations in the Treatment of Febrile Neutropenic Patients**, 5th Meeting of the Mediteranian Blood Club, Antalya, Turkey, 21- 24 Sep 1990.
52. **Ferhanoğlu B**, Tabak F, Avanoğlu Y, Aktuğlu G, Ulutin ON, Akman N; **Comparison of Aclacynomycin +ARA-C Versus DAT Combination Chemotherapy in the Treatment of ANLL**, 5th Meeting of the Mediterranean Blood Club, Antalya, Turkey, 21- 24 Sep 1990.

- 53.** Soysal T, Avanoğlu Y, **Ferhanoğlu B**, Ülkü B, Aktuğlu G, Ulutin ON, Akman N; **A Retrospective Study of 96 Cases of Chronic Lymphocytic Leukemia**, 5th Meeting of The Mediterranean Blood Club, Antalya, Turkey, 21- 24 Sep 1990.
- 54.** Ulutin ON, Ulutin SB, Uğur MS, Ulutin T, Erbenği T, **Ferhanoğlu B** and Yardımcı T; **Defibrotide and Its Effects on Platelet Functions**, 6th.Meeting of the Danubian League Against Thrombosis and Haemorrhagic Disorders, p.48, Vienna, Austria, 1989.
- 55.** **Ferhanoğlu B**, Avanoğlu Y, Tüzüner N, Erbenği T, Ulutin ON; **Acute Megakaryoblastik Leukemia (Report of A Case). XXII Congress of the International Society of Hematology**, p. 372, Milan, Italy, Aug 28- Sep 2 1988.
- 56.** Ulutin B, Ulutin T, Özsoy Y, **Ferhanoğlu B** and Ulutin ON; **The Effects of Defibrotide on Tissue Plasminogen Activator and Molecular Markers of Platelets. Xth International Congress on Thrombosis**, p.153, Athens, Greece, May 22- 27, 1988.

**Citations – Web of Science – Updated on 6th of March, 2019**

Turkish Society of Hematology

